Advanced Enzyme
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Management at Advanced Enzyme Technologies has acknowledged a challenging start to FY27, citing revenue recognition reversals and geopolitical headwinds, yet remains optimistic about the company's fundamental strengths. The focus on operational efficiencies and leveraging a new R&D facility for product innovation is expected to support revenue growth, particularly in niche markets. Vista's financial outlook reflects moderated revenue growth expectations, with stable margins anticipated as the company navigates external pressures. The strategic emphasis on AI-driven R&D and advanced fermentation technologies aligns with industry trends favoring innovation and sustainability, which could enhance market share. However, the company faces significant headwinds, including rising input costs and tariff-related challenges, which may impact margins and overall performance. Over the next 12-24 months, opportunities lie in expanding into high-potential geographies and launching new products, while watchpoints include geopolitical tensions and supply chain uncertainties that could disrupt operations. Overall, Vista's forecast indicates a cautious but steady path forward, with a target price reflecting a modest upside potential
Why We Like This Stock
- Management's focus on operational efficiencies and product innovation through a new R&D facility is expected to drive revenue growth
- The company's diversified business model and strategic investments in AI-driven R&D align with industry trends, enhancing competitive positioning
- Expansion into high-potential geographies and new product launches could unlock significant market opportunities
Things To Watch Out For
- Geopolitical tensions and rising input costs are likely to exert pressure on profit margins in the near term
- Tariff-related challenges in the Americas may hinder market performance and pricing power
- Supply chain uncertainties could disrupt operations and impact working capital management
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 624 | 637 | 746 | 739 | 805 |
| Profit Before Tax (Cr.) | 203 | 187 | 222 | 214 | 234 |
| PBT Margin | 32.6% | 29.3% | 29.7% | 28.9% | 29.1% |
| Net Profit (Cr.) | 143 | 138 | 168 | 162 | 173 |
| Earnings Per Share | 12.4 | 12.1 | 14.6 | 14.1 | 15.4 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers serratiopeptidase, fungal lactase, peptizyme SP, nattokinase, fungal lipase, alpha galactosidase, saccharomyces boulardii, hemicellulose, papain, bromelain, fungal proteases, and bacterial alpha amylase. It also provides probiotics for human and animal nutrition. In addition, the company offers enzymes and probiotics for fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, oils and fats processing, biofuels, and specialty applications. Further, it provides non-food processing enzymes for textile, leather, and pulp and paper processing, as well as detergents and cleaning aids. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.